Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06235125 · ClinicalTrials.gov registry record · Phase 1
Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
A Phase 1 study of Osteosarcoma and Pediatrics, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06235125 is a Phase 1 study of Osteosarcoma and Pediatrics that is actively recruiting participants, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 10 participants, below the 302-participant average among 46 other Osteosarcoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06235125, a Phase 1 study of Osteosarcoma and Pediatrics, is actively recruiting participants, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Pediatric subjects aged 6-17 with biopsy confirmed cancer and imaging findings suspicious for pulmonary metastatic disease scheduled to undergo pulmonary metastasectomy via and open or minimally invasive approach.
Conditions Studied
Interventions
- DRUG Cytalux
Study Locations (1)
Illinois
- Ann & Robert H. Lurie Children's Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-04-08 |
| Est. Completion | 2026-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06235125
The ClinicalTrials.gov registry entry for NCT06235125 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 46 other Osteosarcoma trials with a reported enrollment target (97% lower). The listed sponsor is Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Osteosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Cytalux is the first listed.
NCT06235125 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06235125 about?
NCT06235125 is a clinical study titled "Safety and Feasibility of Intraoperative Visualization With Cytalux in Children". Pediatric subjects aged 6-17 with biopsy confirmed cancer and imaging findings suspicious for pulmonary metastatic disease scheduled to undergo pulmonary metastasectomy via and open or minimally invasive approach.
What is the current status of trial NCT06235125?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-04-08. Estimated completion is 2026-01-20.
What conditions does trial NCT06235125 study?
This clinical trial studies the following conditions: Osteosarcoma, Pediatrics, Metastatic Sarcoma, Pulmonary Metastasis, Fluorescence.
What interventions are being tested in trial NCT06235125?
The interventions under investigation include: Cytalux (DRUG).
Who is sponsoring clinical trial NCT06235125?
This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06235125 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Losartan + Sunitinib in Treatment of Osteosarcoma
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.